MBX Biosciences (MBX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Apr, 2026Voting matters and shareholder proposals
Election of two Class II Directors, Patrick J. Heron and Edward T. Mathers, to serve until the 2029 Annual Meeting or until successors are elected and qualified.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Audit committee and external auditor matters
Proposal to ratify Ernst & Young LLP as the external auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MBX Biosciences
- Virtual meeting to elect directors and ratify auditor, with robust governance and compliance.MBX
Proxy filing22 Apr 2026 - Advanced clinical pipeline and raised capital, supporting operations into 2029.MBX
Q4 202512 Mar 2026 - Phase III for once-weekly PTH therapy and monthly obesity treatments advance with key data in 2024.MBX
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Phase three in hypoparathyroidism advances on schedule; obesity pipeline and funding remain strong.MBX
The Citizens Life Sciences Conference 202610 Mar 2026 - Phase III and obesity data milestones, robust pipeline, and strong cash position drive outlook.MBX
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Late-stage trials and new obesity programs advance, leveraging peptide tech for long-acting dosing.MBX
44th Annual J.P. Morgan Healthcare Conference2 Mar 2026 - Major clinical milestones and strong financials position for leadership in endocrine and obesity therapies.MBX
Oppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026 - Advancing once-weekly endocrine therapies with strong financial backing and key 2025 catalysts.MBX
Guggenheim Inaugural Global Healthcare Innovation Conference14 Jan 2026 - Lead programs in endocrine and metabolic diseases target major unmet needs with innovative dosing.MBX
Stifel 2024 Healthcare Conference13 Jan 2026